

Martha Q Lacy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7752132/publications.pdf>

Version: 2024-02-01

433
papers

11,870
citations

47006
47
h-index

33894
99
g-index

437
all docs

437
docs citations

437
times ranked

8928
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	5.2	7
2	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
3	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	7.2	12
4	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
5	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
7	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
8	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	7.2	7
9	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
10	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . Leukemia, 2022, 36, 1429-1431.	7.2	8
11	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
12	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	5.2	13
13	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	2.4	6
14	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	2.4	0
15	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	6.2	3
16	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	1.3	2
17	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Advances, 2022, 6, 5429-5435.	5.2	3
18	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Outcomes of multiple myeloma patients with 17p undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
20	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
21	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
22	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
23	Implications of detecting serum monoclonal protein by MASS-Fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
24	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
25	Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2021, 56, 978-979.	2.4	0
26	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
27	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	1.2	1
28	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
29	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
30	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
31	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12
32	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	6.2	10
33	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
34	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
35	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
36	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25

#	ARTICLE	IF	CITATIONS
37	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.8	5
38	Synchronous pityriasis lichenoides et varioliformis acuta and lymphoplasmacytic lymphoma: a distinct association. <i>International Journal of Dermatology</i> , 2021, 60, 1550-1552.	1.0	0
39	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
40	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
41	Belantamab mafodotin detection by MASS-FIX and immunofixation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e430-e433.	2.3	1
42	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.4	9
43	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	1.2	3
44	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	5.2	13
45	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	1.3	2
46	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	4.1	21
47	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	2.5	12
48	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	6.2	9
49	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	1.2	6
50	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	4.1	8
51	Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100473.	1.7	4
52	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, .	4.1	6
53	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	1.4	3
54	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	1.4	0

#	ARTICLE	IF	CITATIONS
55	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). Blood, 2021, 138, 1333-1333.	1.4	0
56	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
57	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \geq 100. Blood, 2021, 138, 1617-1617.	1.4	0
58	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	1.4	1
59	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	1.4	0
60	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
61	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
62	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
63	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
64	Prognostic Factors for Early (\leq 2 years) and Late (\geq 5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
65	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	1.4	0
66	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	1.4	1
67	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0
68	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
69	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0
70	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
71	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
72	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25

#	ARTICLE	IF	CITATIONS
73	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
74	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	4.1	10
75	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
76	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
77	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
78	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
79	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
80	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
81	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
82	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
83	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
84	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
85	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
86	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
87	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
88	Holistic review for hematology-oncology fellowship applicants: A new paradigm?. American Journal of Hematology, 2020, 95, 1124-1126.	4.1	1
89	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
90	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59

#	ARTICLE	IF	CITATIONS
91	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
92	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	2.4	8
93	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
94	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
95	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
96	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
97	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
98	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. Scientific Reports, 2020, 10, 10250.	3.3	19
99	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
100	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
101	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
102	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
103	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
104	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	5.2	8
105	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 2020, 10, 41.	6.2	24
106	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	1.4	4
107	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
108	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
110	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
111	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3
112	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	1.4	1
113	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
114	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. Journal of the Advanced Practitioner in Oncology, 2020, 11, 395-400.	0.4	1
115	PET Imaging of a Unique Case of Multiple Myeloma in an Adolescent. Clinical Nuclear Medicine, 2020, 45, 730-731.	1.3	1
116	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
117	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
118	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
119	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. Blood, 2020, 136, 34-35.	1.4	0
120	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
121	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
122	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0
123	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	1.4	0
124	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
125	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
126	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
128	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	1.4	0
129	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
130	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
131	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	4.1	18
132	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594.	2.4	9
133	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
134	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
135	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
136	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
137	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	4.1	7
138	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	4.1	36
139	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	4.1	14
140	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
141	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
142	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
143	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	1.3	4
144	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9

#	ARTICLE	IF	CITATIONS
145	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. British Journal of Haematology, 2019, 185, 701-707.	2.5	17
146	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
147	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	2.4	9
148	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
149	Substratification of patients with newly diagnosed standard-risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	2.5	12
150	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7
151	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	4.1	17
152	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	7.2	12
153	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
154	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
155	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
156	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
157	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	2.4	7
158	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
159	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
160	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
161	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	7.2	72
162	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	1.4	1
164	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. Blood, 2019, 134, 1846-1846.	1.4	2
165	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	1.4	2
166	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864.	1.4	13
167	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	1.4	2
168	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	3.0	16
169	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	1.4	0
170	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	0
171	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
172	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	1.4	0
173	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	1.4	0
174	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
175	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
176	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	1.4	0
177	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	1.4	1
178	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
179	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
180	The Transcriptome of Immunomodulator-Resistant Multiple Myeloma. Blood, 2019, 134, 1772-1772.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma. <i>Blood</i> , 2019, 134, 3061-3061.	1.4	0
182	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013.	1.4	0
183	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	1.4	1
184	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	7.2	8
185	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	7.2	64
186	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	3.5	10
187	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	4.1	14
188	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
189	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	1.8	71
190	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	7.2	28
191	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	2.4	4
192	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	3.0	16
193	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	2.5	15
194	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	3.0	57
195	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	4.1	49
196	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	4.1	57
197	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	4.1	11
198	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	6.2	16

199	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
200	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
201	Utility and prognostic value of ¹⁸ F-CD20 positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
202	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
203	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
204	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
205	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
206	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
207	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
208	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
209	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
210	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
211	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
212	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
213	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
214	Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
215	Depth of Response in Waldenström Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
216	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
218	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
219	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	1.4	0
220	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
221	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
222	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	1.4	0
223	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0
224	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
225	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	0
226	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
227	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
228	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	1.4	0
229	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
230	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
231	Prognosis of Patients with Waldenstrom Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
232	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. Blood, 2018, 132, 2236-2236.	1.4	0
233	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
234	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2017, 58, 308-315.	1.3	16

#	ARTICLE	IF	CITATIONS
235	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
236	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	4.1	16
237	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	1.4	249
238	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	3.0	4
239	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	3.0	1
240	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	4.1	5
241	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	4.1	75
242	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.0	115
243	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	4.1	24
244	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
245	First report of MYD88 ^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.	3.0	10
246	Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.	1.3	2
247	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	2.5	15
248	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	3.5	29
249	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.5	25
250	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	4.1	25
251	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	3.0	4
252	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	1.4	54

#	ARTICLE	IF	CITATIONS
253	Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. American Journal of Hematology, 2017, 92, 220-221.	4.1	30
254	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
255	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41
256	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
257	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer, 2016, 122, 2197-2205.	4.1	37
258	Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. American Journal of Hematology, 2016, 91, 571-574.	4.1	75
259	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
260	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
261	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.8	22
262	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38
263	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
264	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
265	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
266	Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN γ -NIS. Human Gene Therapy Clinical Development, 2016, 27, 111-122.	3.1	47
267	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 872-878.	3.5	19
268	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
269	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	1.4	17
270	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30

#	ARTICLE	IF	CITATIONS
271	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.7	25
272	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	1.4	1
273	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	1.4	4
274	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	1.4	2
275	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	1.4	1
276	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	1.4	3
277	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	1.4	5
278	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	1.4	1
279	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	1.4	1
280	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	1.4	0
281	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	1.4	0
282	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	1.4	0
283	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	1.4	0
284	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	1.4	0
285	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	1.4	0
286	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	1.4	0
287	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	1.4	0
288	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	1.4	0
290	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	1.4	0
291	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	1.4	0
292	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267.	1.4	0
293	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	4.1	18
294	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	4.1	38
295	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015, 56, 3357-3364.	1.3	36
296	Clinical course and prognosis of nonsecretory multiple myeloma. <i>European Journal of Haematology</i> , 2015, 95, 57-64.	2.2	50
297	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	3.0	92
298	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	3.0	106
299	Severe Reversible Pulmonary Hypertension in Smoldering Multiple Myeloma: Two Cases and Review of the Literature. <i>Pulmonary Circulation</i> , 2015, 5, 211-216.	1.7	6
300	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.4	10
301	Soluble suppression of tumorigenicity 2 (sTSG2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	4.1	31
302	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	1.4	6
303	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	1.4	1
304	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	1.4	8
305	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	1.4	3
306	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	1.4	5

#	ARTICLE	IF	CITATIONS
307	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. Blood, 2015, 126, 1839-1839.	1.4	1
308	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	1.4	0
309	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	1.4	0
310	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	1.4	0
311	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	1.4	0
312	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	1.4	0
313	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	1.4	0
314	Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood, 2014, 124, 536-545.	1.4	190
315	The clinical significance of cereblon expression in multiple myeloma. Leukemia Research, 2014, 38, 23-28.	0.8	84
316	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	3.0	240
317	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
318	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	1.6	147
319	Pomalidomide. Blood, 2013, 122, 2305-2309.	1.4	75
320	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	1.4	3
321	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
322	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	1.4	2
323	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	1.4	3
324	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	1.4	7

#	ARTICLE	IF	CITATIONS
325	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	1.4	12
326	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	1.4	9
327	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
328	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
329	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	1.4	0
330	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	1.4	0
331	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	1.4	0
332	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	1.6	837
333	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	1.4	218
334	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	1.4	2
335	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. Blood, 2012, 120, 194-194.	1.4	11
336	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. Blood, 2012, 120, 201-201.	1.4	16
337	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. Blood, 2012, 120, 3138-3138.	1.4	26
338	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	1.4	7
339	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	1.4	1
340	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Blood, 2012, 120, LBA-6-LBA-6.	1.4	14
341	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2012, 120, 2973-2973.	1.4	16
342	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0

#	ARTICLE	IF	CITATIONS
343	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	1.4	0
344	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. Blood, 2012, 120, 599-599.	1.4	0
345	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	1.4	0
346	TEMPI: A Reversible Syndrome Following Treatment with Bortezomib. Blood, 2012, 120, 986-986.	1.4	1
347	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	3.0	164
348	Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leukemia and Lymphoma, 2011, 52, 560-566.	1.3	10
349	New Immunomodulatory Drugs in Myeloma. Current Hematologic Malignancy Reports, 2011, 6, 120-125.	2.3	9
350	Acute Lung Toxicity Related to Pomalidomide. Chest, 2011, 140, 529-533.	0.8	32
351	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	1.4	1
352	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	1.4	2
353	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.	1.4	1
354	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	1.4	1
355	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.	1.4	4
356	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	1.4	3
357	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. Blood, 2011, 118, 2945-2945.	1.4	1
358	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	1.4	5
359	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	1.4	0
360	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	1.4	0

#	ARTICLE	IF	CITATIONS
361	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	1.4	8
362	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.	1.4	0
363	IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.	1.4	0
364	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	1.4	0
365	Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. American Journal of Hematology, 2010, 85, 95-96.	4.1	18
366	Discordance between serum cardiac biomarker and immunoglobulinâ€free lightâ€chain response in patients with immunoglobulin lightâ€chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 2010, 85, 757-759.	4.1	111
367	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. Blood, 2010, 116, 1892-1892.	1.4	2
368	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. Blood, 2010, 116, 1893-1893.	1.4	1
369	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.	1.4	5
370	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	1.4	1
371	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	1.4	1
372	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.	1.4	4
373	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	1.4	1
374	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	1.4	0
375	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. Blood, 2010, 116, 3047-3047.	1.4	0
376	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. Blood, 2010, 116, 4518-4518.	1.4	0
377	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. Blood, 2010, 116, 2253-2253.	1.4	5
378	Unraveling Early Mortality In Patients with AL Amyloidosis. Blood, 2010, 116, 4990-4990.	1.4	4

#	ARTICLE	IF	CITATIONS
379	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. Blood, 2010, 116, 2970-2970.	1.4	1
380	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. Blood, 2010, 116, 987-987.	1.4	1
381	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. Blood, 2010, 116, 3468-3468.	1.4	0
382	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. Blood, 2010, 116, 1958-1958.	1.4	0
383	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. Blood, 2010, 116, 3554-3554.	1.4	13
384	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. Blood, 2010, 116, 3469-3469.	1.4	0
385	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. Blood, 2010, 116, 3572-3572.	1.4	6
386	Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group. Leukemia Research, 2009, 33, 1485-1489.	0.8	45
387	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	1.4	1
388	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	1.4	2,022
389	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	1.6	152
390	Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. Blood, 2008, 112, 2744-2744.	1.4	6
391	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. Blood, 2008, 112, 95-95.	1.4	3
392	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. Blood, 2008, 112, 2301-2301.	1.4	0
393	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	143
394	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings, 2007, 82, 1179-1184.	3.0	142
395	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	155
396	Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.. Blood, 2007, 110, 1171-1171.	1.4	2

#	ARTICLE	IF	CITATIONS
397	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. Blood, 2007, 110, 2477-2477.	1.4	1
398	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. Blood, 2007, 110, 3601-3601.	1.4	4
399	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. Blood, 2007, 110, 1181-1181.	1.4	0
400	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	1.4	0
401	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	1.4	0
402	Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL).. Blood, 2006, 108, 5125-5125.	1.4	0
403	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. Blood, 2006, 108, 3500-3500.	1.4	0
404	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
405	Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation. Archives of Dermatology, 2005, 141, 1277-82.	1.4	60
406	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. Blood, 2005, 106, 3475-3475.	1.4	6
407	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	1.4	5
408	6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.. Blood, 2005, 106, 986-986.	1.4	2
409	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5420-5420.	1.4	0
410	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	1.4	0
411	Response to Rituximab in Type II Cryoglobulinemia.. Blood, 2005, 106, 3499-3499.	1.4	0
412	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. Blood, 2005, 106, 1173-1173.	1.4	1
413	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. Blood, 2005, 106, 2567-2567.	1.4	2
414	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. Blood, 2005, 106, 5422-5422.	1.4	0

#	ARTICLE	IF	CITATIONS
415	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 3751-3757.	1.6	774
416	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2004, 104, 2927-2927.	1.4	1
417	Combination Therapy with CC-5013 (Lenalidomide; Revlimid [®] , [©]) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004, 104, 331-331.	1.4	16
418	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004, 104, 892-892.	1.4	2
419	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. <i>Blood</i> , 2004, 104, 928-928.	1.4	0
420	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. <i>Blood</i> , 2004, 104, 1493-1493.	1.4	0
421	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. <i>Blood</i> , 2004, 104, 2412-2412.	1.4	1
422	Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 4852-4852.	1.4	0
423	A high bone marrow plasma cell labeling index in stable plateau [®] phase multiple myeloma is a marker for early disease progression and death. <i>Blood</i> , 2001, 97, 2522-2523.	1.4	50
424	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001, 68, 269-275.	4.1	61
425	Fatal Pulmonary Toxicity Related to the Administration of Granulocyte Colony-Stimulating Factor in Amyloidosis: A Report and Review of Growth Factor-Induced Pulmonary Toxicity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 635-643.	1.8	35
426	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 262-262.	1.6	77
427	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	1.6	64
428	Comparison of Interleukin-1 β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Blood</i> , 1999, 93, 300-305.	1.4	75
429	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999, 93, 1062-1066.	1.4	180
430	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	1.3	31
431	Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 73-77.	1.0	91
432	Comparison of Interleukin-1 β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Blood</i> , 1999, 93, 300-305.	1.4	2

#	ARTICLE	IF	CITATIONS
433	Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). , 1997, 56, 288-293.		54